In this study, we evaluated the pharmacokinetic profiles of meloxicam and sustained-release (SR) buprenorphine in prairie dogs. The 4 treatment groups were: low-dose meloxicam (0.2 mg/kg SC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback